Related Experiment Videos
Work and productivity loss in the rizatriptan multiple attack study
E J Dasbach1, G W Carides, W C Gerth
1Merck & Co, Inc, Blue Bell, PA 19422, USA. erik_dasbach@merck.com
Cephalalgia : an International Journal of Headache
|February 13, 2001
Summary
Rizatriptan treatment significantly reduced work loss and improved productivity in patients with acute migraine. This migraine medication decreased absenteeism and enhanced on-the-job effectiveness, benefiting employed individuals.
Area of Science:
- Neurology
- Pharmacology
- Occupational Health
Background:
- Migraine significantly impacts work productivity and causes absenteeism.
- Quantifying the economic burden of migraine on paid work is crucial.
Purpose of the Study:
- To measure the self-reported effect of acute migraine and its treatment on paid work and productivity loss.
- To assess the impact of rizatriptan on migraine-related work absenteeism and productivity.
Main Methods:
- A randomized, double-blind, placebo-controlled, crossover study.
- 407 patients aged 18-65 with moderate to severe migraines completed a self-administered questionnaire.
- Patients treated four separate migraine attacks with either rizatriptan 10 mg or placebo.
Main Results:
- Rizatriptan use was associated with 0.7 fewer hours of absenteeism and 0.4 fewer hours of lost productive time per attack compared to placebo (P < 0.01).
- Total work loss per migraine attack was reduced by 1.1 hours with rizatriptan versus placebo (P < 0.01).
- Rizatriptan significantly decreased migraine-related work loss and improved on-the-job effectiveness.
Conclusions:
- Rizatriptan effectively reduces the impact of acute migraine on paid work and productivity.
- Treatment with rizatriptan can mitigate economic losses associated with migraine absenteeism and reduced work effectiveness.